ATHENA Trial

Summary: Evaluated dronedarone versus placebo in patients with paroxysmal or persistent atrial fibrillation. There was a 24% relative risk reduction in cardiovascular hospitalization or death, 30% reduction in cardiovascular death, 45% reduction in deaths from arrhythmia and a non-significant 17% reduction in all-cause mortality.

Original Publication:

N Engl J Med. 2009 Feb 12;360(7):668-78.

http://www.ncbi.nlm.nih.gov/pubmed/21870978

Eponym: A Trial with Dronedarone to Prevent Hospitalization or DEath in PatieNts With Atrial Fibrillation